Status:
COMPLETED
A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19
Lead Sponsor:
Korea University Guro Hospital
Conditions:
COVID-19
Eligibility:
All Genders
19-80 years
Phase:
PHASE2
Brief Summary
According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effec...
Eligibility Criteria
Inclusion
- Patients with mild COVID-19 (NEWS scoring system 0-4)
- Patient within 7 days from symptom onset or Patient within 48 hous after laboratory diagnosis (SARS-CoV-2 RT-PCR)
Exclusion
- Hypoxia (SaO2 \<95%)
- Unable to take oral medication
- Unable to use inhaler
- Pregnancy or breast feeding
- Immunocompromising conditions
- Moderate/severe renal dysfunction : creatinine clearance (CCL) \< 30 mL/min
- Moderate/severe liver dysfunction: AST or ALT \> 5 times upper normal limit
- Asthma or chronic obstructive lung disease
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04330586
Start Date
April 1 2020
End Date
March 31 2021
Last Update
June 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Guro Hospital
Seoul, South Korea